{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:34:00Z","timestamp":1789569240777,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10620-026-09804-x","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:59:58Z","timestamp":1772726398000},"page":"3361-3368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Effectiveness of Biologic Therapies in Chronic Pouchitis and Crohn\u2019s-Like Disease of the Pouch: A Bi-center Retrospective Cohort Study"],"prefix":"10.1007","volume":"71","author":[{"given":"Yoav","family":"Uchitel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel Aviv","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Tulchinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Zemel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzvi","family":"Har-Shefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Koslowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lael","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitsan","family":"Maharshak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"9804_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/bmj.2.6130.85","volume":"2","author":"AG Parks","year":"1978","unstructured":"Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. Br Med J 1978;2:85\u201390. https:\/\/doi.org\/10.1136\/bmj.2.6130.85.","journal-title":"Br Med J"},{"key":"9804_CR2","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.cgh.2013.03.033","volume":"11","author":"B Shen","year":"2013","unstructured":"Shen B. Pouchitis: what every gastroenterologist needs to know. Clin Gastroenterol Hepatol 2013;11:1538\u20131549. https:\/\/doi.org\/10.1016\/j.cgh.2013.03.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9804_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/codi.15995","volume":"24","author":"D Sriranganathan","year":"2022","unstructured":"Sriranganathan D, Kilic Y, Quraishi MN, Segal JP. Prevalence of pouchitis in ulcerative colitis and familial adenomatous polyposis: systematic review and meta-analysis. Colorectal Dis 2022;24:13\u201323. https:\/\/doi.org\/10.1111\/codi.15995.","journal-title":"Colorectal Dis"},{"key":"9804_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrgastro.2012.58","volume":"9","author":"B Shen","year":"2012","unstructured":"Shen B. Acute and chronic pouchitis: pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 2012;9:323\u2013333. https:\/\/doi.org\/10.1038\/nrgastro.2012.58.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"9804_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/ecco-jcc\/jjw157","volume":"11","author":"N Maharshak","year":"2017","unstructured":"Maharshak N, Cohen NA, Reshef L et al. Alterations of enteric microbiota in patients with a normal ileal pouch are predictive of pouchitis. J Crohns Colitis 2017;11:314\u2013320. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw157.","journal-title":"J Crohns Colitis"},{"key":"9804_CR6","first-page":"4829","volume":"14","author":"LMV de Negreiros","year":"2022","unstructured":"de Negreiros LMV, Pascoal LB, Genaro LM et al. Pouchitis: insight into pathogenesis and clinical aspects. Am J Transl Res 2022;14:4829\u20134844.","journal-title":"Am J Transl Res"},{"key":"9804_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2468-1253(21)00214-4","volume":"7","author":"B Shen","year":"2022","unstructured":"Shen B, Kochhar GS, Rubin DT et al. Treatment of pouchitis, Crohn\u2019s disease, cuffitis, and other inflammatory disorders of the pouch: International Ileal Pouch Consortium consensus. Lancet Gastroenterol Hepatol 2022;7:69\u201395. https:\/\/doi.org\/10.1016\/S2468-1253(21)00214-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9804_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/ibd\/izx049","volume":"24","author":"M Huguet","year":"2018","unstructured":"Huguet M, Pereira B, Goutte M et al. Anti-TNF therapy in refractory pouchitis and Crohn\u2019s disease-like complications of the pouch: systematic review and meta-analysis. Inflamm Bowel Dis 2018;24:261\u2013268. https:\/\/doi.org\/10.1093\/ibd\/izx049.","journal-title":"Inflamm Bowel Dis"},{"key":"9804_CR9","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/ibd\/izz030","volume":"25","author":"M Gregory","year":"2019","unstructured":"Gregory M, Weaver KN, Hoversten P et al. Efficacy of vedolizumab for refractory pouchitis: multicenter US cohort. Inflamm Bowel Dis 2019;25:1569\u20131576. https:\/\/doi.org\/10.1093\/ibd\/izz030.","journal-title":"Inflamm Bowel Dis"},{"key":"9804_CR10","doi-asserted-by":"publisher","unstructured":"Outtier A, Louis E, Dewit O, et al. 2023 Effectiveness of ustekinumab for chronic antibiotic-refractory pouchitis. J Crohns Colitis 17(Suppl 1):S651. Abstract. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0651","DOI":"10.1093\/ecco-jcc\/jjac190.0651"},{"key":"9804_CR11","doi-asserted-by":"publisher","unstructured":"Salem G, Brewer GG, Limketkai BN, et al. 2021 Use of biologics for inflammatory conditions of the pouch: systematic review. Gastroenterology 160(Suppl 1):S-779. Abstract. https:\/\/doi.org\/10.1016\/S0016-5085(21)01550-X","DOI":"10.1016\/S0016-5085(21)01550-X"},{"key":"9804_CR12","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa2208450","volume":"388","author":"S Travis","year":"2023","unstructured":"Travis S, Silverberg MS, Danese S et al. Vedolizumab for chronic pouchitis. N Engl J Med 2023;388:1321\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa2208450.","journal-title":"N Engl J Med"},{"key":"9804_CR13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.14309\/ajg.0000000000003608","volume":"117","author":"EL Barnes","year":"2022","unstructured":"Barnes EL, Raffals L, Qazi T et al. Prospective comparison of ustekinumab and anti-TNF therapy in Crohn\u2019s-like disease of the pouch. Am J Gastroenterol 2022;117:1430\u20131439. https:\/\/doi.org\/10.14309\/ajg.0000000000003608.","journal-title":"Am J Gastroenterol"},{"key":"9804_CR14","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1097\/MIB.0000000000000712","volume":"22","author":"AL Lightner","year":"2016","unstructured":"Lightner AL, Pemberton JH, Loftus EV Jr. Crohn\u2019s disease of the ileoanal pouch. Inflamm Bowel Dis 2016;22:1502\u20131508. https:\/\/doi.org\/10.1097\/MIB.0000000000000712.","journal-title":"Inflamm Bowel Dis"},{"key":"9804_CR15","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1111\/j.1572-0241.2003.07675.x","volume":"98","author":"JF Colombel","year":"2003","unstructured":"Colombel JF, Ricart E, Loftus EV Jr et al. Management of Crohn\u2019s disease of the ileoanal pouch with infliximab. Am J Gastroenterol 2003;98:2239\u20132244. https:\/\/doi.org\/10.1111\/j.1572-0241.2003.07675.x.","journal-title":"Am J Gastroenterol"},{"key":"9804_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2147\/CEG.S219556","volume":"14","author":"A Outtier","year":"2021","unstructured":"Outtier A, Ferrante M. Chronic antibiotic-refractory pouchitis: management challenges. Clin Exp Gastroenterol 2021;14:277\u2013290.","journal-title":"Clin Exp Gastroenterol"},{"key":"9804_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0025-6196(12)61634-6","volume":"69","author":"WJ Sandborn","year":"1994","unstructured":"Sandborn WJ, Tremaine WJ, Batts KP et al. Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 1994;69:409\u2013415. https:\/\/doi.org\/10.1016\/S0025-6196(12)61634-6.","journal-title":"Mayo Clin Proc"},{"key":"9804_CR18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s10350-004-6652-8","volume":"46","author":"B Shen","year":"2003","unstructured":"Shen B, Achkar JP, Connor JT et al. Modified pouchitis disease activity index. Dis Colon Rectum 2003;46:748\u2013753. https:\/\/doi.org\/10.1007\/s10350-004-6652-8.","journal-title":"Dis Colon Rectum"},{"key":"9804_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14309\/ajg.0000000000003055","volume":"120","author":"M Kayal","year":"2025","unstructured":"Kayal M, Posner H, Jimenez D et al. Endoscopic response reduces subsequent pouchitis risk. Am J Gastroenterol 2025;120:251\u2013253. https:\/\/doi.org\/10.14309\/ajg.0000000000003055.","journal-title":"Am J Gastroenterol"},{"key":"9804_CR20","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.cgh.2021.09.045","volume":"20","author":"JE Ollech","year":"2022","unstructured":"Ollech JE, Rubin DT, Shen B et al. Fecal calprotectin is increased in pouchitis and progressively increases with more severe endoscopic and histologic disease. Clin Gastroenterol Hepatol 2022;20:1839\u20131846. https:\/\/doi.org\/10.1016\/j.cgh.2021.09.045.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9804_CR21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/ajg.2014.242","volume":"109","author":"JF Colombel","year":"2014","unstructured":"Colombel JF, Sandborn WJ, Ghosh S et al. Four-year maintenance with adalimumab in ulcerative colitis. Am J Gastroenterol 2014;109:1771\u20131780. https:\/\/doi.org\/10.1038\/ajg.2014.242.","journal-title":"Am J Gastroenterol"},{"key":"9804_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Van Assche G, Reinisch W et al. Adalimumab induces and maintains remission in ulcerative colitis. Gastroenterology 2012;142:257\u2013265. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.032.","journal-title":"Gastroenterology"},{"key":"9804_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1215734.","journal-title":"N Engl J Med"},{"key":"9804_CR24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr et al. Vedolizumab vs adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019;381:1215\u20131226. https:\/\/doi.org\/10.1056\/NEJMoa1905725.","journal-title":"N Engl J Med"},{"key":"9804_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.dld.2022.01.127","volume":"54","author":"FS Macaluso","year":"2022","unstructured":"Macaluso FS, Orlando A, Papi C et al. Biologics and small molecules for ulcerative colitis: IG-IBD guidelines. Dig Liver Dis 2022;54:418\u2013429. https:\/\/doi.org\/10.1016\/j.dld.2022.01.127.","journal-title":"Dig Liver Dis"},{"key":"9804_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J et al. ECCO guidelines on therapeutics in ulcerative colitis. J Crohns Colitis 2022;16:2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178.","journal-title":"J Crohns Colitis"},{"key":"9804_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G et al. ECCO guidelines on therapeutics in Crohn\u2019s disease. J Crohns Colitis 2020;14:4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"key":"9804_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab induction and maintenance for ulcerative colitis. N Engl J Med 2019;381:1201\u20131214. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"9804_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/2050640619895361","volume":"8","author":"T Ochsenk\u00fchn","year":"2020","unstructured":"Ochsenk\u00fchn T, Tillack C, Szokodi D et al. Ustekinumab rescue in refractory ulcerative colitis. United European Gastroenterol J 2020;8:91\u201398. https:\/\/doi.org\/10.1177\/2050640619895361.","journal-title":"United European Gastroenterol J"},{"key":"9804_CR30","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.cgh.2020.07.008","volume":"19","author":"M Kayal","year":"2021","unstructured":"Kayal M, Lambin T, Plietz M et al. Recycling of precolectomy anti-TNF in chronic pouch inflammation is associated with treatment failure. Clin Gastroenterol Hepatol 2021;19:1491-1493.e3. https:\/\/doi.org\/10.1016\/j.cgh.2020.07.008.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9804_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/ecco-jcc\/jjw134","volume":"11","author":"L Robbins","year":"2017","unstructured":"Robbins L, Zaghiyan K, Melmed G et al. Outcomes with anti\u2013tumour necrosis factor-alpha therapy and serology in de novo Crohn\u2019s disease after ileal pouch-anal anastomosis. J Crohns Colitis 2017;11:77\u201383. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw134.","journal-title":"J Crohns Colitis"},{"key":"9804_CR32","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2018-317246","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W et al. Expansion of IL-23R TNFR21 T cells and anti-TNF resistance. Gut 2019;68:814\u2013828. https:\/\/doi.org\/10.1136\/gutjnl-2018-317246.","journal-title":"Gut"},{"key":"9804_CR33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1053\/j.gastro.2024.05.010","volume":"167","author":"S Cao","year":"2024","unstructured":"Cao S, Nguyen KM, Ma K et al. Mucosal single-cell profiling of Crohn\u2019s-like disease of the pouch. Gastroenterology 2024;167:1399\u20131414. https:\/\/doi.org\/10.1053\/j.gastro.2024.05.010.","journal-title":"Gastroenterology"},{"key":"9804_CR34","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/ibd\/izab123","volume":"31","author":"M Kayal","year":"2025","unstructured":"Kayal M, Spencer EA, Smyth M et al. Risankizumab for Crohn\u2019s disease of the pouch. Inflamm Bowel Dis 2025;31:878\u2013881. https:\/\/doi.org\/10.1093\/ibd\/izab123.","journal-title":"Inflamm Bowel Dis"},{"key":"9804_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2401234","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel JF et al. Risankizumab vs ustekinumab in Crohn\u2019s disease. N Engl J Med 2024;391:213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa2401234.","journal-title":"N Engl J Med"},{"key":"9804_CR36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.0856","volume":"332","author":"E Louis","year":"2024","unstructured":"Louis E, Schreiber S, Panaccione R et al. Risankizumab for ulcerative colitis: two randomized trials. JAMA 2024;332:881\u2013897. https:\/\/doi.org\/10.1001\/jama.2024.0856.","journal-title":"JAMA"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09804-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09804-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09804-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:01:28Z","timestamp":1787540488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09804-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9804"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09804-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NM has received speaking and\/or consulting fees from Pfizer, AbbVie, Eli Lilly, Takeda, Janssen, Ferring, BMS, Nestle, and grant support from Takeda, Janssen, Abbott, AbbVie, Pfizer, BMS, and Nestle. NAC has received speaking and\/or consulting fees from Abbvie, Takeda, BMS, Rafa Pharmaceuticals and Iterative Health, a grant support from Takeda and travel support from Pfizer and Takeda.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}